Vor Bio启动1亿美元普通股发行计划

波士顿 - Vor Biopharma Inc. (NASDAQ:VOR) 周一宣布已开始进行1亿美元普通股的承销公开发行。这家临床阶段生物技术公司还计划授予承销商30天期权，可额外购买价值1500万美元的股票。根据 InvestingPro 数据显示，该公司目前市值仅为1.2954亿美元，此次发行对公司而言是一次重大融资，尽管其资产负债表上"现金消耗迅速"，但仍持有比债务更多的现金。

Vor Biopharma股价因1亿美元公开发行计划暴跌

Investing.com -- Vor Biopharma Inc (NASDAQ:VOR) 股价在周一盘后交易中暴跌14.9%，此前这家临床阶段生物技术公司宣布计划公开发行1亿美元的普通股。 这家自身免疫疾病治疗开发商表示，计划发行价值1亿美元的普通股，并为承销商提供30天的额外选择权，可以按公开发行价格减去承销折价和佣金购买最多1500万美元的额外股份。拟议发行的所有股份将由Vor ...
钛媒体APP on MSN

Vor反手给了荣昌生物一拳

不知道荣昌生物后悔了没有。

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

J.P. Morgan, Jefferies, Citigroup and TD Cowen are acting as joint book-running managers for the offering.

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

J.P. Morgan, Jefferies, Citigroup and TD Cowen are acting as joint book-running managers for the proposed offering.
Seeking Alpha

Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...
TipRanks on MSN

Vor Biopharma Appoints New Chief Medical Officer

On November 2, 2025, Vor Biopharma Inc. amended the employment agreement with its Chief Development Officer, Dr. Qing Zuraw, to include additional severance benefits in case of termination without ...

Vor Biopharma slumps 26%, prices $100M equity at $10 per share

Clinical-stage biotechnology company Vor Biopharma (VOR) priced an underwritten public offering of 10M shares at $10.00 per share. The gross proceeds from the offering are expected to be $100 million.